文献速递甲状腺疾病

细胞学不确定甲状腺结节中核异型性与癌症风险:系统综述与Meta分析

Cancer Risk Associated with Nuclear Atypia in Cytologically Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis.
PubMed 文献 · Thyroid · 2017-12-21

该系统综述与Meta分析检索PubMed和EMBASE,纳入20项研究、3532个细胞学不确定甲状腺结节(B-III或B-IV类),比较有核异型性与无核异型性结节的恶性风险。作者认为核异型性是细胞学不确定甲状腺结节恶性的显著指标,需要标准化并应用于临床实践。

要点

  • Meta分析纳入20项研究、3532个结节,其中1162个有核异型性、2370个无核异型性。
  • 异质性不显著(I²<0.01%,p=0.40),无发表偏倚证据。

核心结论

  • 核异型性是细胞学不确定甲状腺结节恶性的显著指标,需要标准化并应用于临床实践。

研究设计与样本

  • 于2016年6月30日检索PubMed和EMBASE中英文或西班牙文文献,由内分泌科医生和图书馆员制定检索策略,未设日期限制,并筛查纳入研究的参考文献。
  • 纳入报告经组织学确认的细胞学不确定甲状腺结节伴或不伴核异型性恶性患病率的研究;排除可疑恶性结节、重复活检为非不确定(B-III或B-IV)细胞学的结节、非连续评估的结节及与更大系列重叠的队列。
  • 两名研究者独立评估纳入资格和偏倚风险,遵循PRISMA和MOOSE指南;由一名研究者提取汇总数据、另一名独立审核,采用随机效应模型合并数据,通过亚组分析和混合效应模型Meta回归探索异质性。

主要发现

  • 共检索到2571项研究,其中20项符合纳入标准。
  • Meta分析基于3532个细胞学不确定甲状腺结节的汇总数据:1162个有核异型性,2370个无核异型性。
  • 无发表偏倚证据,异质性不显著(I²<0.01%,p=0.40)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Indeterminate categories of thyroid cytopathology (categories B-III and B-IV of the Bethesda system) are integrated by a heterogeneous spectrum of cytological scenarios that are generally clustered for analysis and management recommendations. It has been suggested that aspirates exhibiting nuclear atypia have a higher risk of malignancy. This study aimed to assess whether cytologically indeterminate thyroid nodules with nuclear atypia have a significantly higher cancer risk than those without nuclear atypia. METHODS: On June 30, 2016, PubMed and EMBASE were searched for articles in English or Spanish using a search strategy developed by an endocrinologist and a librarian. Case reports were excluded, and no date limits were used. The references of all included studies were also screened for relevant missing studies. Studies were included if the prevalences of malignancy of cytologically indeterminate thyroid nodules with histological confirmation with and without nuclear atypia were reported. Studies were excluded if they had: (i) nodules suspicious for malignancy; (ii) nodules with non-indeterminate (B-III or B-IV) cytology on repeated biopsy, if performed; (iii) nodules not consecutively evaluated; or (iv) cohorts overlapping with another larger series. Two investigators independently assessed the eligibility and risk of bias of the studies. PRISMA and MOOSE guidelines were followed. Summary data were extracted from published reports by one investigator and independently reviewed by another. Data were pooled using a random-effects model. Heterogeneity was explored using subgroup analysis and mixed-effect model meta-regression. The odds ratio for malignancy of cytologically indeterminate thyroid nodules with nuclear atypia over cytologically indeterminate thyroid nodules without nuclear atypia was calculated. RESULTS: Of 2571 retrieved studies, 20 were eligible. The meta-analysis was conducted on summary data of 3532 cytologically indeterminate thyroid nodules: 1162 with and 2370 without nuclear atypia. The odds ratio for malignancy in cytologically indeterminate thyroid nodules with nuclear atypia was 3.63 [confidence interval 3.06-4.35]. There was no evidence of publication bias, and heterogeneity was insignificant (I2 < 0.01%, p = 0.40). CONCLUSIONS: Nuclear atypia is a significant indicator of malignancy in cytologically indeterminate thyroid nodules and needs to be standardized and implemented into clinical practice.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Valderrabano P, Khazai L, Thompson ZJ, et al. Cancer Risk Associated with Nuclear Atypia in Cytologically Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis. Thyroid. 2017. PMID: 29160163. doi:10.1089/thy.2017.0419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。